Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 11/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205541 | 0.83 | S1PR1 (0.51) | DHODHS1PR1THRATHRBS1PR4 | |
| SCHEMBL206224 | 0.82 | S1PR1 (0.54) | S1PR1KDM4EMAPTTHRATHRB | |
| SCHEMBL4210034 | 0.81 | S1PR1 (0.48) | DHODHS1PR1THRATHRBS1PR4 | |
| SCHEMBL10190510 | 0.80 | S1PR1 (0.53) | DHODHS1PR1ALDH1A1MAPTTHRA | |
| SCHEMBL3129516 | 0.79 | S1PR1 (0.48) | S1PR1ALDH1A1LMNAMAPTTHRA | |
| SCHEMBL207599 | 0.79 | S1PR1 (0.56) | DHODHS1PR1KDM4EALDH1A1THRA | |
| SCHEMBL207683 | 0.79 | S1PR1 (0.49) | S1PR1ALDH1A1LMNAMAPTTHRA | |
| SCHEMBL208472 | 0.78 | S1PR1 (0.52) | DHODHS1PR1KDM4EMAPTTHRA | |
| SCHEMBL2697750 | 0.78 | S1PR1 (0.52) | S1PR1KDM4EMAPTTHRATHRB | |
| SCHEMBL206582 | 0.78 | S1PR1 (0.54) | S1PR1KDM4EALDH1A1MAPTTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | DHODH 1219/4885S1PR1 1259/4885KDM4E 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.